Imlunestrant
Drug timelines are a Plus or Pro feature.
8 regulatory and trial events tracked for Imlunestrant, covering 2025-07-11 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer [Phase 2]